Osteoporosis management in patients with breast cancer: EMAS position statement

Eastell "Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230)" J. Bone Miner. Res. (2006) 10.1359/jbmr.060508

[3]

Coleman "Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study" Lancet Oncol. (2007) 10.1016/s1470-2045(07)70003-7

[4]

Goss "Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17" J. Natl. Cancer Inst. (2005) 10.1093/jnci/dji250

[5]

Gonnelli "Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane" Bone (2007) 10.1016/j.bone.2006.06.027

[6]

Hadji "Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy" Ann. Oncol. (2009) 10.1093/annonc/mdn762

[7]

Gnant "Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial" Lancet (2015) 10.1016/s0140-6736(15)60995-3

[8]

Saarto "The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer" Br. J. Cancer (2001) 10.1054/bjoc.2001.1729

[9]

Confavreux "Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates" Bone (2007) 10.1016/j.bone.2007.06.004

[10]

Lester "Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer" Clin. Cancer Res. (2008) 10.1158/1078-0432.ccr-07-5101

[11]

Hines "Phase III randomised, placebo-controlled double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer" J. Clin. Oncol. (2009) 10.1200/jco.2008.19.1783

[12]

Van Poznak "Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial" J. Clin. Oncol. (2010) 10.1200/jco.2009.24.5902

[13]

Markopoulos "Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial" Breast Cancer Res. (2010) 10.1186/bcr2565

[14]

Sestak "Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial" Lancet Oncol. (2014) 10.1016/s1470-2045(14)71035-6

[15]

Brufsky "Zoledronic acid inhibits adjuvant letrozole induced bone loss in postmenopausal women with early breast cancer" J. Clin. Oncol. (2007) 10.1200/jco.2005.05.3744

[16]

Bundred "Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results" Cancer (2008) 10.1002/cncr.23259

[17]

Eidtman "Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study" Ann. Oncol. (2010) 10.1093/annonc/mdq217

[18]

Brufsky "Final 5-year results of Z-FAST trial adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole" Cancer (2012) 10.1002/cncr.26313

[19]

Llombart "Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial" Clin. Breast Cancer (2012) 10.1016/j.clbc.2011.08.002

[20]

Coleman "Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results" Ann. Oncol. (2013) 10.1093/annonc/mds277

[21]

Wagner-Johnston "5-year follow-up of a randomised controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (alliance) trial" Cancer (2015) 10.1002/cncr.29327

[22]

Majithia "Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up" Support. Care Cancer (2016)

[23]

Gnant "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy" Lancet Oncol. (2008) 10.1016/s1470-2045(08)70204-3

[24]

Gnant "Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12" Ann. Oncol. (2015) 10.1093/annonc/mdu544

[25]

Hadji "Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study" Osteoporos. Int. (2014) 10.1007/s00198-013-2615-z

[26]

Kalder "Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy" Osteoporos. Int. (2015) 10.1007/s00198-014-2955-3

[27]

Lee "Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients" Breast Cancer Res. Treat. (2011) 10.1007/s10549-011-1728-3

[28]

Bouvard "Fracture incidence after 3 years of aromatase inhibitor therapy" Ann. Oncol. (2014) 10.1093/annonc/mdu008

[29]

Chen "Fracture risk among breast cancer survivors: results from the women’s health initiative observational study" Arch. Intern. Med. (2005) 10.1001/archinte.165.5.552

[30]

Cooke "Tamoxifen use and osteoporotic fracture risk: a population-based analysis" J. Clin. Oncol. (2008) 10.1200/jco.2007.15.7123

[31]

Vestergaard "Fracture risk in patients with different types of cancer" Acta Oncol. (2009) 10.1080/02841860802167490

[32]

Ellis "Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer" J. Clin. Oncol. (2008) 10.1200/jco.2008.16.3832

[33]

Ellis "Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study" Breast Cancer Res. Treat. (2009) 10.1007/s10549-009-0352-y

[34]

Meads "The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance" Clin. Cancer Res. (2008) 10.1158/1078-0432.ccr-07-2223

[35]

Paget "The distribution of secondary growths in cancer of the breast" Lancet (1889) 10.1016/s0140-6736(00)49915-0

[36]

Gnant "Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature" Cancer Treat. Rev. (2012) 10.1016/j.ctrv.2011.09.003

[37]

Diel "Reduction in new metastases in breast cancer with adjuvant clodronate treatment" N. Engl. J. Med. (1998) 10.1056/nejm199808063390601

[38]

Powles "Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]" Breast Cancer Res. (2006) 10.1186/bcr1384

[39]

Paterson "Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial" Lancet Oncol. (2012) 10.1016/s1470-2045(12)70226-7

[40]

Coleman "Breast-cancer adjuvant therapy with zoledronic acid" N. Engl. J. Med. (2011) 10.1056/nejmoa1105195

[41]

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) "Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials" Lancet (2015) 10.1016/s0140-6736(15)60908-4

[42]

Lipton "Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials" Eur. J. Cancer (2012) 10.1016/j.ejca.2012.08.002

[43]

Tremollieres "Screening for osteoporosis after breast cancer: for whom, why and when" Maturitas (2014) 10.1016/j.maturitas.2014.08.001

[44]

Bouvard "High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy" Ann. Oncol. (2012) 10.1093/annonc/mdr356

[45]

Burstein "American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer" J. Clin. Oncol. (2010) 10.1200/jco.2009.26.3756

[46]

Hadji "Practical guidance for the management of aromatase inhibitor-associated bone loss" Ann. Oncol. (2008) 10.1093/annonc/mdn164

[47]

Hadji "Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment" Ann. Oncol. (2011) 10.1093/annonc/mdr017

[48]

Reid "Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group" Cancer Treat. Rev. (2008) 10.1016/j.ctrv.2008.03.007

[49]

Rizzoli "Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper" Osteoporos. Int. (2012) 10.1007/s00198-011-1870-0

[50]

Coleman "Bone health in cancer patients: ESMO clinical practice guidelines" Ann. Oncol. (2014)

Showing 50 of 53 references

Cited By

45

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians

Amir Qaseem, Lauri A. Hicks · 2023

Annals of Internal Medicine

DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study

Vanessa Rouach, Yona Greenman · 2023

Journal of Bone Oncology

Metrics

45

Citations

53

References

Details

Published: Jan 01, 2017
Vol/Issue: 95
Pages: 65-71
License: View

Authors

F

Florence A. Trémollieres

Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece,

A

Alfred Mueck

F

Faustino R. Pérez-López

Y

Yvonne T. van der Schouw

Cite This Article

Florence A. Trémollieres, Iuliana Ceausu, Herman Depypere, et al. (2017). Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas, 95, 65-71. https://doi.org/10.1016/j.maturitas.2016.10.007

Osteoporosis management in patients with breast cancer: EMAS position statement

You May Also Like